University of Montpellier-ko ikertzaileekin lankidetzan egindako argitalpenak (2)

2017

  1. Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial

    The Lancet HIV, Vol. 4, Núm. 9, pp. e384-e392

2016

  1. Short Communication: High Viral Load and Multidrug Resistance Due to Late Switch to Second-Line Regimens Could Be a Major Obstacle to Reach the 90-90-90 UNAIDS Objectives in Sub-Saharan Africa

    AIDS Research and Human Retroviruses, Vol. 32, Núm. 12, pp. 1159-1162